IONS Ionis Pharmaceuticals Inc

Dawnzera is priced at $57,462 per dose, with peak annual sales estimated at $509 million by 2032. Takeda's Takhzyro sales rose 3.7% to 55.1 billion yen in Q2 2025 despite rising competition. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →

Dawnzera cut monthly HAE attacks by 81% vs placebo in Phase 3, with up to 87% reduction after second dose. Patients switching from Takhzyro or Orladeyo saw a 62% lower HAE attack rate with Dawnzera. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here →

Ionis Pharmaceuticals Inc. IONS closed regular trading at $42.81, up 0.78% for the day, before gaining an additional 2.38% in premarket trading to $43.83, according to Benzinga Pro data, following disclosure of insider trading activity by its chief scientific officer.

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

Ionis Pharmaceuticals ( NASDAQ:IONS ) , a biotechnology company focused on RNA-targeted therapeutics, reported its second quarter 2025 earnings on July 30, 2025. The headline news was a substantial beat on both GAAP revenue and non-GAAP earnings compared to Wall Street estimates.

Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.